<?xml version='1.0' encoding='utf-8'?>
<document id="21928040"><sentence text="Effects of sertraline on the pharmacokinetics of bupropion and its major metabolite, hydroxybupropion, in mice."><entity charOffset="11-21" id="DDI-PubMed.21928040.s1.e0" text="sertraline" /><entity charOffset="49-58" id="DDI-PubMed.21928040.s1.e1" text="bupropion" /><entity charOffset="85-101" id="DDI-PubMed.21928040.s1.e2" text="hydroxybupropion" /><pair ddi="false" e1="DDI-PubMed.21928040.s1.e0" e2="DDI-PubMed.21928040.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21928040.s1.e0" e2="DDI-PubMed.21928040.s1.e1" /><pair ddi="false" e1="DDI-PubMed.21928040.s1.e0" e2="DDI-PubMed.21928040.s1.e2" /><pair ddi="false" e1="DDI-PubMed.21928040.s1.e1" e2="DDI-PubMed.21928040.s1.e1" /><pair ddi="false" e1="DDI-PubMed.21928040.s1.e1" e2="DDI-PubMed.21928040.s1.e2" /></sentence><sentence text="Sertraline potently inhibits cytochrome P450 2B6 (CYP2B6) in vitro"><entity charOffset="0-10" id="DDI-PubMed.21928040.s2.e0" text="Sertraline" /></sentence><sentence text=" Bupropion is commonly co-prescribed with sertraline and is exclusively metabolized by CYP2B6 to its major active metabolite hydroxybupropion"><entity charOffset="1-10" id="DDI-PubMed.21928040.s3.e0" text="Bupropion" /><entity charOffset="42-52" id="DDI-PubMed.21928040.s3.e1" text="sertraline" /><entity charOffset="125-141" id="DDI-PubMed.21928040.s3.e2" text="hydroxybupropion" /><pair ddi="false" e1="DDI-PubMed.21928040.s3.e0" e2="DDI-PubMed.21928040.s3.e0" /><pair ddi="false" e1="DDI-PubMed.21928040.s3.e0" e2="DDI-PubMed.21928040.s3.e1" /><pair ddi="false" e1="DDI-PubMed.21928040.s3.e0" e2="DDI-PubMed.21928040.s3.e2" /><pair ddi="false" e1="DDI-PubMed.21928040.s3.e1" e2="DDI-PubMed.21928040.s3.e1" /><pair ddi="false" e1="DDI-PubMed.21928040.s3.e1" e2="DDI-PubMed.21928040.s3.e2" /></sentence><sentence text=" Putatively the co-administration of bupropion and sertraline could lead to a significant pharmacokinetic drug-drug interaction"><entity charOffset="37-46" id="DDI-PubMed.21928040.s4.e0" text="bupropion" /><entity charOffset="51-61" id="DDI-PubMed.21928040.s4.e1" text="sertraline" /><pair ddi="false" e1="DDI-PubMed.21928040.s4.e0" e2="DDI-PubMed.21928040.s4.e0" /><pair ddi="false" e1="DDI-PubMed.21928040.s4.e0" e2="DDI-PubMed.21928040.s4.e1" /></sentence><sentence text=" The aim of this study was to evaluate a possible drug interaction between these drugs in mice" /><sentence text=" To study this male CF-1 mice were administered sertraline 5 mg/kg once daily for 6 days, followed by a single dose of bupropion 50 mg/kg on the seventh study day"><entity charOffset="48-58" id="DDI-PubMed.21928040.s6.e0" text="sertraline" /><entity charOffset="119-128" id="DDI-PubMed.21928040.s6.e1" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.21928040.s6.e0" e2="DDI-PubMed.21928040.s6.e0" /><pair ddi="false" e1="DDI-PubMed.21928040.s6.e0" e2="DDI-PubMed.21928040.s6.e1" /></sentence><sentence text=" Plasma and brain samples were collected post-bupropion dose for measurement of bupropion and hydroxybupropion levels on HPLC"><entity charOffset="46-55" id="DDI-PubMed.21928040.s7.e0" text="bupropion" /><entity charOffset="80-89" id="DDI-PubMed.21928040.s7.e1" text="bupropion" /><entity charOffset="94-110" id="DDI-PubMed.21928040.s7.e2" text="hydroxybupropion" /><pair ddi="false" e1="DDI-PubMed.21928040.s7.e0" e2="DDI-PubMed.21928040.s7.e0" /><pair ddi="false" e1="DDI-PubMed.21928040.s7.e0" e2="DDI-PubMed.21928040.s7.e1" /><pair ddi="false" e1="DDI-PubMed.21928040.s7.e0" e2="DDI-PubMed.21928040.s7.e2" /><pair ddi="false" e1="DDI-PubMed.21928040.s7.e1" e2="DDI-PubMed.21928040.s7.e1" /><pair ddi="false" e1="DDI-PubMed.21928040.s7.e1" e2="DDI-PubMed.21928040.s7.e2" /></sentence><sentence text=" Pharmacokinetic parameters for bupropion and hydroxybupropion were calculated using noncompartmental analysis and the variance in AUC of each was computed using Bailer's analysis"><entity charOffset="32-41" id="DDI-PubMed.21928040.s8.e0" text="bupropion" /><entity charOffset="46-62" id="DDI-PubMed.21928040.s8.e1" text="hydroxybupropion" /><pair ddi="false" e1="DDI-PubMed.21928040.s8.e0" e2="DDI-PubMed.21928040.s8.e0" /><pair ddi="false" e1="DDI-PubMed.21928040.s8.e0" e2="DDI-PubMed.21928040.s8.e1" /></sentence><sentence text=" We found that mice pretreated with sertraline exhibited a small elevation in bupropion metabolism"><entity charOffset="36-46" id="DDI-PubMed.21928040.s9.e0" text="sertraline" /><entity charOffset="78-87" id="DDI-PubMed.21928040.s9.e1" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.21928040.s9.e0" e2="DDI-PubMed.21928040.s9.e0" /><pair ddi="false" e1="DDI-PubMed.21928040.s9.e0" e2="DDI-PubMed.21928040.s9.e1" /></sentence><sentence text=" This was substantiated by Bailer's analysis which indicated that in the presence of sertraline, both plasma and brain bupropion exposure were significantly (p &lt; 0"><entity charOffset="85-95" id="DDI-PubMed.21928040.s10.e0" text="sertraline" /><entity charOffset="119-128" id="DDI-PubMed.21928040.s10.e1" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.21928040.s10.e0" e2="DDI-PubMed.21928040.s10.e0" /><pair ddi="false" e1="DDI-PubMed.21928040.s10.e0" e2="DDI-PubMed.21928040.s10.e1" /></sentence><sentence text="05) decreased, while plasma hydroxybupropion exposure was significantly (p &lt; 0"><entity charOffset="28-44" id="DDI-PubMed.21928040.s11.e0" text="hydroxybupropion" /></sentence><sentence text="05) increased" /><sentence text=" Also the plasma hydroxybupropion-to-bupropion ratio of AUC was increased by 27% in sertraline treated mice, indicative of increased CYP2B activity"><entity charOffset="17-33" id="DDI-PubMed.21928040.s13.e0" text="hydroxybupropion" /><entity charOffset="37-46" id="DDI-PubMed.21928040.s13.e1" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.21928040.s13.e0" e2="DDI-PubMed.21928040.s13.e0" /><pair ddi="false" e1="DDI-PubMed.21928040.s13.e0" e2="DDI-PubMed.21928040.s13.e1" /></sentence><sentence text=" This is the first study, to our knowledge, that reports a mild pharmacokinetic drug-drug interaction between bupropion and sertraline in mice"><entity charOffset="110-119" id="DDI-PubMed.21928040.s14.e0" text="bupropion" /><entity charOffset="124-134" id="DDI-PubMed.21928040.s14.e1" text="sertraline" /><pair ddi="false" e1="DDI-PubMed.21928040.s14.e0" e2="DDI-PubMed.21928040.s14.e0" /><pair ddi="false" e1="DDI-PubMed.21928040.s14.e0" e2="DDI-PubMed.21928040.s14.e1" /></sentence><sentence text=" However, it is unknown whether these quantitative changes in enzyme activity and consequent drug exposure would equate to significant pharmacodynamic changes (e" /><sentence text="g" /><sentence text=", perturbations in brain neurotransmitter levels) observed in the clinic" /><sentence text="" /></document>